Vivian Rexroad, PharmD

CRS:

JHU

Role:

Pharmacy

Position:

Pharmacist, PharmD, Investigational Drug Pharmacy

Email:

vrexroa@jhmi.edu
  • Network Pharmacist, IMPAACT Leadership
  • Member, IMPAACT Multidisciplinary Protocol Review Group
  • Protocol team member for IMPAACT 1078, IMPAACT 1114,  IMPAACT 2000 and IMPAACT 2011
  • General Member (Pharmacist), Protocol Development and Implementation Subcommittee of the SMCCC (Mar 2016-Nov 2019)
  • Member, Pharmacy Working Group of the Protocol Development and Implementation Subcommittee (Mar 2016-Nov 2019)
  • Protocol team member, IMPAACT 2012
  • Protocol team member, IMPAACT 2013
  • Protocol team member, IMPAACT 2018
  • Protocol team member, IMPAACT 2021

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More